Literature DB >> 24328466

Clinical practice. Cervical-cancer screening with human papillomavirus and cytologic cotesting.

Mark Schiffman, Diane Solomon.   

Abstract

Entities:  

Mesh：

Year:  2013        PMID： 24328466     DOI： 10.1056/NEJMcp1210379

Source DB:  PubMed          Journal:  N Engl J Med        ISSN： 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  35 in total

1.  HPV16 CpG methyl-haplotypes are associated with cervix precancer and cancer in the Guanacaste natural history study.

Authors:  Marina Frimer; Chang Sun; Thomas McAndrew; Benjamin Smith; Ariana Harari; Zigui Chen; Lisa Mirabello; Nicolas Wentzensen; Gary L Goldberg; Ana C Rodriguez; Mark Schiffman; Robert D Burk
Journal:  Gynecol Oncol       Date:  2015-05-19       Impact factor: 5.482

2.  Digital diffraction analysis enables low-cost molecular diagnostics on a smartphone.

Authors:  Hyungsoon Im; Cesar M Castro; Huilin Shao; Monty Liong; Jun Song; Divya Pathania; Lioubov Fexon; Changwook Min; Maria Avila-Wallace; Omar Zurkiya; Junsung Rho; Brady Magaoay; Rosemary H Tambouret; Misha Pivovarov; Ralph Weissleder; Hakho Lee
Journal:  Proc Natl Acad Sci U S A       Date:  2015-04-13       Impact factor: 11.205

3.  Cost-Effectiveness of Primary HPV Testing, Cytology and Co-testing as Cervical Cancer Screening for Women Above Age 30 Years.

Authors:  Xian Wen Jin; Laura Lipold; Julie Foucher; Andrea Sikon; Jennifer Brainard; Jerome Belinson; Sarah Schramm; Kelly Nottingham; Bo Hu; Michael B Rothberg
Journal:  J Gen Intern Med       Date:  2016-07-14       Impact factor: 5.128

Review 4.  Cancer Prevention: Lessons Learned and Future Directions.

Authors:  Barbara K Dunn; Barnett S Kramer
Journal:  Trends Cancer       Date:  2016-12

Review 5.  Epidemiology of Human Papillomavirus-Positive Head and Neck Squamous Cell Carcinoma.

Authors:  Maura L Gillison; Anil K Chaturvedi; William F Anderson; Carole Fakhry
Journal:  J Clin Oncol       Date:  2015-09-08       Impact factor: 44.544

6.  MicroRNA-215 is a potential prognostic marker for cervical cancer.

Authors:  Hua Liang; Yan Li; Ruo-Yu Luo; Fu-Jin Shen
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2014-04-08

Review 7.  Prophylactic and Therapeutic HPV Vaccines: Current Scenario and Perspectives.

Authors:  Yicheng Mo; Jiabing Ma; Hongtao Zhang; Junjie Shen; Jun Chen; Juan Hong; Yanmin Xu; Cheng Qian
Journal:  Front Cell Infect Microbiol       Date:  2022-07-04       Impact factor: 6.073

8.  Comparison of primary cytology, primary HPV testing and co-testing as cervical cancer screening for Chinese women: a population-based screening cohort.

Authors:  Zhi-Fang Li; Xin-Hua Jia; Xiangxian Feng; Shaokai Zhang; Xun Zhang; Qin-Jing Pan; Xun-Wen Zou; Yue-Qing Hao; Xi-Bin Sun; You-Lin Qiao
Journal:  BMJ Open       Date:  2022-10-17       Impact factor: 3.006

9.  Molecular analysis of human papillomavirus in never-smokers with non-small cell lung cancer.

Authors:  Shun-Ichi Isa; Yu Kurahara; Satomi Yamamoto; Akihiro Tamiya; Naoki Omachi; Kazuhiro Asami; Kyoichi Okishio; Tomoki Utsumi; Norimasa Ito; Hyung-Eun Yoon; Akihide Matsumura; Shinji Atagi; Tomoya Kawaguchi
Journal:  Oncol Lett       Date:  2014-11-19       Impact factor: 2.967

Review 10.  Prevalence of human papillomavirus genotypes among African women with normal cervical cytology and neoplasia: a systematic review and meta-analysis.

Authors:  Rebecca Kemunto Ogembo; Philimon Nyakauru Gona; Alaina J Seymour; Henry Soo-Min Park; Paul A Bain; Louise Maranda; Javier Gordon Ogembo
Journal:  PLoS One       Date:  2015-04-14       Impact factor: 3.240
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.